Paxista Nirmatrelvir 150mg Tablets & Ritonavir 100mg Tablets, 30 – Covid medicine
$120
Primovir Nirmatrelvir 150mg Tablets & Ritonavir 100mg Tablets:
Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir combination used to treat COVID-19 and sold under the brand name Paxlovid.
Paxista Nirmatrelvir 150mg Tablets Description :
Nirmatrelvir is an oral protease inhibitor that is dynamic against MPRO, a viral protease that assumes a fundamental part in viral replication by cutting the 2 viral polyproteins.1 It has exhibited antiviral movement against all Covids that are known to taint humans.2 Nirmatrelvir is bundled with ritonavir (as Paxlovid), a solid cytochrome P450 (CYP) 3A4 inhibitor and pharmacokinetic helping specialist that has been utilized to support HIV protease inhibitors. Coadministration of ritonavir is expected to increment nirmatrelvir focuses to the objective remedial reach. The Food and Medication Organization (FDA) gave a Crisis Use Approval (EUA) for ritonavir-supported nirmatrelvir on December 22, 2021, for the treatment of Coronavirus.
Brand Name:
Product Specification
| Packaging Size | Combipack |
| Composition | Nirmatrelvir ritonavir |
| Treatment | Covid |
| Prescription/Non prescription | Prescription |
| Form | Tablet |
| Shelf life | Year |
| Drug Name | Paxista |
| Pack Type | 3×10 |
| Packing Type | 3×10 |
| No | N |
Be the first to review “Paxista Nirmatrelvir 150mg Tablets & Ritonavir 100mg Tablets, 30 – Covid medicine”
You must be logged in to post a review.
Related products
Covid medicine
GENERAL MEDICINE
Covid medicine
Covid medicine
Covid medicine
Covid medicine
Reviews
There are no reviews yet.